Scholar Rock (NASDAQ:SRRK) Price Target Raised to $50.00

Scholar Rock (NASDAQ:SRRK) had its target price lifted by HC Wainwright from $40.00 to $50.00 in a report issued on Tuesday, MarketBeat Ratings reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Scholar Rock’s FY2026 earnings at ($1.57) EPS, FY2027 earnings at ($0.78) EPS and FY2028 earnings at $0.18 EPS.

SRRK has been the subject of several other reports. JPMorgan Chase & Co. increased their price objective on Scholar Rock from $18.00 to $31.00 and gave the company an “overweight” rating in a report on Monday, October 14th. Truist Financial raised their price objective on shares of Scholar Rock from $36.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday. Wedbush upped their target price on shares of Scholar Rock from $40.00 to $47.00 and gave the company an “outperform” rating in a report on Monday. BMO Capital Markets raised their price target on Scholar Rock from $34.00 to $38.00 and gave the stock an “outperform” rating in a report on Friday, October 11th. Finally, Piper Sandler upped their price objective on Scholar Rock from $28.00 to $42.00 and gave the company an “overweight” rating in a research note on Tuesday, October 15th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $40.43.

Scholar Rock Stock Up 2.9 %

Scholar Rock stock opened at $38.15 on Tuesday. The stock has a 50-day simple moving average of $24.29 and a 200-day simple moving average of $14.54. The company has a market capitalization of $3.57 billion, a P/E ratio of -16.23 and a beta of 0.47. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. Scholar Rock has a fifty-two week low of $6.76 and a fifty-two week high of $43.38.

Insider Activity

In related news, insider Tracey Sacco sold 30,000 shares of the business’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $25.62, for a total transaction of $768,600.00. Following the sale, the insider now owns 49,285 shares of the company’s stock, valued at approximately $1,262,681.70. The trade was a 37.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Srinivas Akkaraju sold 1,175,713 shares of the stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $29.25, for a total transaction of $34,389,605.25. Following the completion of the transaction, the director now directly owns 5,612,896 shares of the company’s stock, valued at approximately $164,177,208. This trade represents a 17.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,823,322 shares of company stock valued at $56,411,627 in the last three months. 19.20% of the stock is currently owned by company insiders.

Institutional Trading of Scholar Rock

A number of institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Scholar Rock by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,895 shares of the company’s stock worth $25,000 after buying an additional 514 shares in the last quarter. Quarry LP lifted its holdings in shares of Scholar Rock by 3,443.3% in the third quarter. Quarry LP now owns 4,500 shares of the company’s stock valued at $36,000 after purchasing an additional 4,373 shares in the last quarter. Walleye Trading LLC acquired a new stake in shares of Scholar Rock in the first quarter valued at approximately $178,000. Principal Financial Group Inc. purchased a new position in shares of Scholar Rock during the 2nd quarter worth approximately $98,000. Finally, Hsbc Holdings PLC acquired a new position in shares of Scholar Rock during the 2nd quarter worth approximately $100,000. 91.08% of the stock is currently owned by hedge funds and other institutional investors.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.